Celltrion Inc (068270.KS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea · ISIN KR7068270008
Celltrion Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.56 tn KRW | 4.16 tn KRW |
| Gross profit | 1.68 tn KRW | 2.47 tn KRW |
| Operating income | 492.02 bn KRW | 1.16 tn KRW |
| EBIT | 651.69 bn KRW | 1.23 tn KRW |
| Net income | 422.69 bn KRW | 1.03 tn KRW |
| Diluted EPS – continuing operations | 1,964.25 KRW | 4,706.26 KRW |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
More stocks
- Swiss Life Holding AG (SLHN.SW)
- Denso Corp (6902.T)
- Sunbelt Rentals Holdings, Inc. (SUNB)
- Tenaris SA (TEN.MI)
- Adidas (ADS.DE)
- Liberty Media Corp (FWONK)
- Intact Financial Corporation (IFC.TO)
- Huntington Bancshares (HBAN)
- Leonardo SpA (LDO.MI)
- Kyocera Corp (6971.T)
- Daiichi Sankyo Co Ltd (4568.T)
- Imperial Brands PLC (IMB.L)
Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.